Hidradenitis Suppurativa

A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants with Hidradenitis Suppurativa Topical Ruxolitinib Evaluation in Hidradenitis Suppurativa (TRuE-HS1)

• Population: participants at least 12 years of age with a confirmed diagnosis of hidradenitis suppurativa for at least six months at screening

• Study Condition: mild to moderate hidradenitis suppurativa

• Study Design: Phase 3, randomized, vehicle-controlled study in participants at least 12 years of age with a confirmed diagnosis of hidradenitis suppurativa.

• Duration: 16 weeks double blind randomization with vehicle control period followed by 36 weeks of open label extension

• Compensation is provided for participation

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

• Population: Male and female participants aged 12 years or older at the time of enrollment.

• Study Condition: Diagnosis of HS is based on clinical history and physical examination for at least six months before the baseline visit. Participants must have failed respond to or are intolerant of anti-TNF therapy and/ or one approved non-anti-TNF biologic therapy for moderate to severe HS, defined as having a total of at least five and count (abscesses and/or inflammatory nodules) and inflammatory lesions affecting at least two distinct anatomic areas

• Study Design: The Phase 3 study aims to assess the efficacy and safety of Upadacitinib in adult and adolescent patients with moderate to severe hidradenitis suppurativa. This global, double-blind, placebo-controlled study will evaluate Upadacitinib at doses of 30 mg once a day and 15 mg once a day vs matching placebo once a day in participants with moderate to severe HS.

• Compensation may be provided for participation

• Study is currently enrolling

Lutikizumab in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa

• Population: Subjects ≥ 16 years of age

• Study Condition: Moderate to severe hidradenitis suppurativa (HS) for at least 6 months

• Study Design: This is a pivotal Phase 3, global, randomized, double-blinded, placebo-controlled, multicenter study to evaluate efficacy and safety of lutikizumab in subjects 16 years of age and older with moderate to severe HS. The study comprises a 35-day Screening Period, a 16-week placebo-controlled double-blinded period (Period 1), a 36-week double-blinded extension (Period 2), and a 10-week (70 days) Follow-Up Period after last study drug dosing or an option to enter a separate long term extension study.

• Compensation may be provided for participation 

A randomized, double-blind, double-dummy, placebo controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis suppurativa(HS)

• Population: Male and female participants aged 18 years or older at the time of enrollment.

• Study Condition: Diagnosis of HS is based on clinical history and physical examination for at least six months before the baseline visit. Participants must have moderate to severe HS, defined as having a total of at least five and count (abscesses and/or inflammatory nodules) and inflammatory lesions affecting at least two distinct anatomic areas

• Study Design: The Phase 3 study aims to assess the efficacy, safety, and tolerability of remibrutinib in adult patients with moderate to severe hidradenitis suppurativa. This global, double-blind, placebo-controlled study will evaluate remibrutinib at doses of 10 mg twice a day and 25 mg twice a day vs matching placebo twice a day in participants with moderate to severe HS.

• Compensation is provided for participation

• Study is currently enrolling